

# Putative Hormone with Antiobesogenic and Insulin-Sensitizing Effect

---

Šoša, Ivan; Grubešić, Aron

*Source / Izvornik:* **International journal of immunopathology and pharmacology**, 2016, 29, 147 - 148

**Journal article, Published version**

**Rad u časopisu, Objavljena verzija rada (izdavačev PDF)**

<https://doi.org/10.1177/0394632015623796>

*Permanent link / Trajna poveznica:* <https://urn.nsk.hr/urn:nbn:hr:184:570585>

*Rights / Prava:* [Attribution-NonCommercial 4.0 International/Imenovanje-Nekomercijalno 4.0 međunarodna](#)

*Download date / Datum preuzimanja:* **2024-07-27**



*Repository / Repozitorij:*

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



# Putative hormone with anti-obesogenic and insulin-sensitizing effect

Ivan Sosa<sup>1</sup> and Aron Grubesić<sup>2</sup>

International Journal of  
Immunopathology and Pharmacology  
2016, Vol. 29(1) 147–148  
© The Author(s) 2015  
Reprints and permissions:  
sagepub.co.uk/journalsPermissions.nav  
DOI: 10.1177/0394632015623796  
iji.sagepub.com



## Abstract

It was confirmed that bone morphogenetic protein-9 (BMP-9), like insulin, improves glycemia in diabetic mice and regulates glucose metabolism in hepatocytes, which is why it is proposed as a candidate for the hepatic insulin-sensitizing substance (HISS). Regarding the fact that BMP-9 has a signaling pathway similar to other BMPs as well as insulin, it is expected that BMP-9 would also have certain effects on the liver. In our 2011 hypothesis, we aimed towards BMP-9 as a possible “hepatic insulin-sensitizing substance” (HISS) and in this article, we provide further evidence, derived from existing studies, suggesting that this putative hormone might in fact be none other than BMP-9.

## Keywords

BMP-9, endothelium, NO

Date received: 27 October 2015; accepted: 27 November 2015

Bone morphogenetic protein-9 (BMP-9) is a member of transforming growth factor beta (TGF- $\beta$ ) superfamily of cytokines that regulate cell growth and differentiation during embryogenesis. BMP-9 binds to hepatocytes and shows strong immunoreactivity in liver non-parenchymal cells, which corresponds with our attempt to investigate immunolocalization of BMP-9 in the human liver. Indeed in our 2011 hypothesis,<sup>1</sup> we aimed towards BMP-9 as a possible “hepatic insulin-sensitizing substance” (HISS) mainly due to experimental work of Lutt<sup>2</sup> and that of Alam and Sollinger.<sup>3</sup> Furthermore, this hypothesis had been supported and experimentally proven in 2008 by Caperuto et al.<sup>4</sup> It is interesting that Caperuto takes reference on insulin influencing the release of HISS (whatever it may be) through a mechanism which includes the creation of nitric oxide,<sup>1,4</sup> stimulated by acetyl choline. On this role as well as the role of NO as an intermediary in glucose regulation rather than as a new candidate molecule for HISS, Lutt and Caperuto are in agreement. Even Lutt’s opinion on the role of NO in glucose level regulation has not changed when considering his earlier papers.<sup>2,5</sup>

In addition to BMP-9’s inhibition of gluconeogenesis, Cheng et al. have also established it to have an effect on the metabolism of lipids by

changing the expression of key enzymes – malic enzyme (ME) and the fatty acid synthase (FAS).<sup>6</sup> From Chen’s findings, and also according to Alamo et al., the effect of BMP-9 on glucose metabolism is similar to that of insulin. Its effect is only weaker in terms of gluconeogenesis, which is, it would seem the key metabolic link affected by NO derived from nitric oxide synthase 3 (NOS3) enzyme (endothelial NOS or eNOS).

The fact that the endothelial form of NOS is involved in glucose metabolism along with BMP-9 is indeed indicative. BMP-9 has for some time now been called a circulating vascular quiescence factor<sup>7</sup> and most BMPs are also attributed with a certain angiogenic effect of which Huylebroek wrote all the way back in 2007.<sup>8</sup> The key role of endothelia in-between HISS, insulin, gluconeogenesis, obesity, and type 2 diabetes should always be observed in relation with BMP-9, more so as it exercises most of its effect through the ALK1 receptor.<sup>7</sup> These

<sup>1</sup>Clinical Hospital Center Rijeka, Rijeka, Croatia

<sup>2</sup>Department of Internal Medicine, Clinical Hospital Center Rijeka, Rijeka, Croatia

## Corresponding author:

Ivan Sosa, Clinical Hospital Center Rijeka, Kresimirova 42, Rijeka, 51000, Croatia.

Email: ivan.sosa@medri.uniri.hr

receptors, apart from activating SMAD phosphorylation as part of the BMP signal pathway<sup>9</sup> also incite endothelial migration and proliferation.

We, unfortunately, did not aim to document hypoglycemic effect of BMP-9 but rather relied upon observations of Chen et al., where BMP-9 inhibited gluconeogenesis and activated expression of pivotal enzymes in lipid metabolism after a single subcutaneous injection.

Considering the above stated as well as the mitogenic activity of the hepatocytes stimulated by insulin when reversing fibrosis due to porto-caval shunt, we believe that anti-obesogenic and insulin-sensitizing effect that Sansbury and Hill<sup>10</sup> have recently attributed to NO should not be seen monochromatically, more so as it has been becoming clear for years that this putative hormone might in fact be none other than BMP-9.

#### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

#### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

#### References

1. Sosa I, Cvijanovic O, Celic T, et al. (2011) Hepatoregenerative role of bone morphogenetic protein-9. *Medical Science Monitor* 17: Hy33–35.
2. Lutt WW (1999) The HISS story overview: A novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes. *Canadian Journal of Physiology and Pharmacology* 77: 553–562.
3. Alam T and Sollinger HW (2002) Glucose-regulated insulin production in hepatocytes. *Transplantation* 74: 1781–1787.
4. Caperuto LC, Anhe GF, Cambiaghi TD, et al. (2008) Modulation of bone morphogenetic protein-9 expression and processing by insulin, glucose, and glucocorticoids: Possible candidate for hepatic insulin-sensitizing substance. *Endocrinology* 149: 6326–6335.
5. Lutt WW, Ming Z, Macedo MP, et al. (2008) HISS-dependent insulin resistance (HDIR) in aged rats is associated with adiposity, progresses to Syndrome X, and is attenuated by a unique antioxidant cocktail. *Experimental Gerontology* 43: 790–800.
6. Chen C, Grzegorzewski KJ, Barash S, et al. (2003) An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. *Nature Biotechnology* 21: 294–301.
7. David L, Mallet C, Keramidas M, et al. (2008) Bone morphogenetic protein-9 is a circulating vascular quiescence factor. *Circulation Research* 102: 914–922.
8. Huylebroeck D (2007) Bone morphogenetic proteins go endothelial. *Blood* 109: 1794–1795.
9. Mehra A and Wrana JL (2002). TGF-beta and the Smad signal transduction pathway. *Biochemistry and Cell Biology* 80: 605–622.
10. Sansbury BE and Hill BG (2014) Regulation of obesity and insulin resistance by nitric oxide. *Free Radical Biology & Medicine* 73: 383–399.